ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12622001063707

Ethics application status

Approved

Date submitted

26/07/2022

Date registered

1/08/2022

Date last updated

20/01/2023

Date data sharing statement initially provided

1/08/2022

Type of registration

Prospectively registered

Titles & IDs

Public title

BEAT CF: Pulmonary Exacerbations Treatment Platform - Adjunct Antibiotics Domain

Scientific title

BEAT CF: Pulmonary Exacerbations Treatment Platform - Adjunct Antibiotics Domain:
An evaluation of the comparative effectiveness of prescribing various standard of care, adjunct Antibiotics in the management of pulmonary exacerbations requiring intensive therapy (PERIT) in children and adults with CF, with respect to their short-term improvement in lung function.

Secondary ID [1]

Nil known

Universal Trial Number (UTN)

Trial acronym

BEAT CF DSA B - Adjunct antibiotics

Linked study record

This record is a sub-study of ACTRN12621000638831 platform study master protocol.

Health condition

Health condition(s) or problem(s) studied:

Cystic Fibrosis

Condition category

Condition code

Human Genetics and Inherited Disorders

Cystic fibrosis

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The intervention is a Prescription for the Assigned antibiotic (or no Adjunct Antibiotic) at the commencement of intensive therapy made by the Responsible Clinician or their authorised delegate.
For each of the 2 treatment options involving adjunct antibiotics:
The Dose and Duration prescribed is not fixed, and will ultimately be at the discretion of the Responsible Clinician in adherence with local Cystic Fibrosis (CF) centre /hospital guidelines and policies. The protocol requires that the antibiotic has a planned duration of at least 7 days. No maximum duration of treatment is specified. Assigned antibiotics include:

1. Intravenous Tobramycin
As a guide, intravenous (IV) injection over several minutes, OR an IV infusion over up to 1 hour. It may also be given by intramuscular (IM) injection.

2. Inhaled Tobramycin
As a guide, Several formulations are used for inhalational therapy. Generally ampoules for nebulisation are used in preference to capsules for inhalation for PERIT.
500mg/5mL vial - (Tobra-Day); 300mg/5mL ampoule Tobramycin solution for inhalation (various brands), and 28mg capsules for inhalation (Tobi® Podhaler) which is PBS-subsidised for children greater than or equal to 6years old only.

3. No adjunct antibiotic

Adherence to the assigned intervention will be monitored by the detailed information about intensive therapies that is captured in the BEAT CF database. This information will be transcribed from the hospital medical records into the BEAT CF database by dedicated BEAT CF site coordinators at each site.

Participants will only be randomised to one of these treatment arms for any single episode of a pulmonary exacerbation. If participants do not respond to the assigned arm the clinician is free to decide which therapy the participant shall be switched to. There will be no subsequent randomsiations to adjunct antibiotics within a single pulmonary exacerbation episode.

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

1. First randomisation is to clinician's choice (Responsible Clinician’s Selected Intervention) or to a Random intervention (Randomly Assigned Intervention).
The comparator for this randomisation is the Clinician's choice treatment arm.

2. The second randomisation, for those assigned to the Random intervention in step 1, is randomisation to one of 3 interventions:
1. Intravenous tobramycin
2. Inhaled tobramycin
3. No adjunct antibiotic
The comparator for the second randomisation is each of the other arms in this domain. The assigned antibiotic is compared against each of the other options.

The comparator for each arm is each of the other arms in this domain. The assigned antibiotic is compared to the other antibiotic option, and against the no adjunct antibiotic option.

Control group

Active

Outcomes

Primary outcome [1]

The absolute change in the ppFEV1 measured by spirometry

Timepoint [1]

Greater than 7 days but not more than 14 days after first dose of intensive therapy.

Secondary outcome [1]

1. The relative change in the ppFEV1, measured by spirometry and defined as the proportional change (expressed as a percentage) in the ppFEV1 at day 7-10 from day 0.

Timepoint [1]

Approximately 7 days from initiation of intensive therapy.

Secondary outcome [2]

2. Absolute change in the FEV1pp measured by spirometry

Timepoint [2]

Approximately 2 weeks, 4 weeks, 8 weeks, and 24 weeks after commencement of intensive therapy.

Secondary outcome [3]

3. Relative change in the FEV1pp measured by spirometry

Timepoint [3]

Approximately 2 weeks, 4 weeks, 8 weeks, and 24 weeks after commencement of intensive therapy.

Secondary outcome [4]

4. Time taken for FEV1pp measured by spirometry to return to greater than or equal to 90% of the baseline FEV1pp measured by spirometry.

Timepoint [4]

Approximately 1 week, 2 weeks, 4 weeks, 8 weeks, and 24 weeks after commencement of intensive therapy.

Secondary outcome [5]

5. The absolute change in the severity of symptoms of respiratory infection as measured by the Chronic Respiratory Infection Symptom Score (CRISS)

Timepoint [5]

Approximately 7 days, 14 days and 30 days after commencement of intensive therapy.

Secondary outcome [6]

6. The time to next exacerbation measured as the time (in days) from commencement of intensive therapy to the next commencement of intensive therapy after a period of no intensive therapy of > 7 days. This will be determined by data for hospitalisations for lung exacerbations reported in the BEAT CF platform database.

Timepoint [6]

Following a post BEAT CF enrolment hospitalisation for treatment of a lung exacerbation, and a period of no intensive therapy of greater than 7 days after discharge from that exacerbation.

Secondary outcome [7]

7. Any interruption of planned therapy before 7 days (168hr) after commencement of intensive therapy, owing to intolerable effects presumed by the treating clinician to be attributable to therapy. Assessment will be made on data reported in the BEAT CF database.

Timepoint [7]

Post enrolment in BEAT CF, during hospitalisation for a lung exacerbation: after commencement of intensive therapy in that hospitalisation, for up to 7 days from commencement of the intensive therapy

Secondary outcome [8]

9. Health related quality of life, as scored by The Cystic fibrosis Quality of Life questionnaire, revised, (CFQR).

Timepoint [8]

For participants over 6 years of age, every 12 weeks post enrolment in BEAT CF until the participant withdraws consent for continuing or the platform is closed.

Secondary outcome [9]

10. A new detection of any strain of gram negative bacteria with in vitro resistance to any aminoglycoside, fluoroquinolone, antipseudomonal penicillin (including beta-lactam/beta-lactamase inhibitor combination), antipseudomonal cephalosporin, or carbapenem assessed by sputum culture or medical record review.

Timepoint [9]

Any time post enrolment to BEAT CF and for the 2 years prior to enrolment to BEAT CF.

Secondary outcome [10]

11. Any new onset of Clostridium difficile associated diarrhoea assessed by faecal sample post enrolment to BEAT CF, or by medical record review for the 1 year prior to BEAT CF enrolment.

Timepoint [10]

Any time post enrolment to BEAT CF and for the 2 years prior to enrolment to BEAT CF.

Secondary outcome [11]

8. Any interruption of planned therapy before 14 days (336hr) after commencement of intensive therapy, owing to intolerable effects presumed by the treating clinician to be attributable to therapy. Assessment will be made on data reported in the BEAT CF database.

Timepoint [11]

Post enrolment in BEAT CF, during hospitalisation for a lung exacerbation: after commencement of intensive therapy in that hospitalisation, for up to 14 days (336hrs) from commencement of the intensive therapy

Eligibility

Key inclusion criteria

1. Be enrolled in the BEAT CF PEx Cohort (ACTRN12621000638831).
2. Documented informed consent to participate in the Adjunct antibiotic Domain.
3. Are eligible for at least two Interventions in the Adjunct Antibiotic Domain available at the clinical Site (including no Adjunct Antibiotic).
4. Must be able to reliably perform spirometry.

Minimum age

5 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

1. The person is unable to reliably perform spirometry (for example due to young age)
2. The person’s Responsible Clinician deems enrolment in the PEx Adjunct Antibiotic Domain is not in their best interest.

A participant will be excluded from Assignment to a specific Intervention in the Adjunct Antibiotic Domain if:
1. They have a known or suspected significant drug hypersensitivity to tobramycin or other aminoglycosides
2. Recognised contraindication to IV tobramycin, including known renal, auditory or vestibular impairment which, in the opinion of the Responsible Clinician, precludes its use.
3. The Intervention is deemed unacceptable by the Responsible Clinician e.g. because of a poor treatment response to that antibiotic (requiring a change in antibiotic treatment) in the preceding 12 months

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Participants will be randomised 1:4 to either be Provisionally Assigned the Selected Regimen (“‘Clinician’s Choice”) or to be Provisionally Assigned a Randomly Assigned Regimen, for each Domain they are eligible for, and participating in. Prior to the Assignment being Revealed, it will be considered ‘Provisionally Assigned’.

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Other

Other design features

Assignment to a Randomly Assigned Regimen will occur using response-adaptive randomisation (RAR). In RAR, the ratio of allocation to each Regimen varies over time in response to the accumulating data, such that the probability of Assignment to a Regimen is proportional to the posterior probability that, at the most recent Scheduled Analysis, it is the Best Regimen. When RAR is implemented, the initial allocation ratios will be equal across Regimens.

Phase

Not Applicable

Type of endpoint/s

Efficacy

Statistical methods / analysis

A Bayesian linear model will be used for the primary analysis. This model is used to estimate the mean change in ppFEV1 from Day 0 (primary endpoint) for each regimen in each Stratum. These estimates can then be used to compare response to treatment for different Regimens or Interventions in each Stratum.
The Primary Endpoint aligns with the endpoint used in the recent STOP studies. The STOP Study Investigators used change in FEV1 as a proportion (percentage) of that predicted based on sex, age and height (ppFEV1), from the time of commencement of therapy (or admission) as the most appropriate measure of improved lung function. In that prospective study of North American adults with CF, the mean absolute change in ppFEV1 was 8.4 after 7 days of therapy, with a standard deviation of 11.3.

Recruitment

Recruitment status

Recruiting

Date of first participant enrolment

Anticipated

5/09/2022

Actual

7/09/2022

Date of last participant enrolment

Anticipated

30/04/2024

Actual

Date of last data collection

Anticipated

31/05/2024

Actual

Sample size

Target

5000

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

NSW,QLD,SA,WA,VIC

Recruitment hospital [1]

The Children's Hospital at Westmead - Westmead

Recruitment hospital [2]

Sydney Children's Hospital - Randwick

Recruitment hospital [3]

Royal Prince Alfred Hospital - Camperdown

Recruitment hospital [4]

Queensland Children's Hospital - South Brisbane

Recruitment hospital [5]

Mater Private Hospital - South Brisbane

Recruitment hospital [6]

Womens and Childrens Hospital - North Adelaide

Recruitment hospital [7]

Perth Children's Hospital - Nedlands

Recruitment hospital [8]

Sir Charles Gairdner Hospital - Nedlands

Recruitment hospital [9]

The Royal Childrens Hospital - Parkville

Recruitment hospital [10]

John Hunter Hospital - New Lambton

Recruitment hospital [11]

John Hunter Children's Hospital - New Lambton

Recruitment postcode(s) [1]

2145 - Westmead

Recruitment postcode(s) [2]

2031 - Randwick

Recruitment postcode(s) [3]

2050 - Camperdown

Recruitment postcode(s) [4]

4101 - South Brisbane

Recruitment postcode(s) [5]

5006 - North Adelaide

Recruitment postcode(s) [6]

6009 - Nedlands

Recruitment postcode(s) [7]

3052 - Parkville

Recruitment postcode(s) [8]

2305 - New Lambton

Funding & Sponsors

Funding source category [1]

Government body

Name [1]

Commonwealth of Australia as represented by the Department of Health

Address [1]

23 Furzer St Woden ACT 2606

Country [1]

Australia

Primary sponsor type

University

Name

University of Sydney

Address

Level 3, F23 Michael Spence Administration Building,
Corner of Eastern Avenue and City
Road, The University of Sydney,
NSW 2006 Australia

Country

Australia

Secondary sponsor category [1]

None

Name [1]

Address [1]

Country [1]

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Child and Adolescent Health Services Human Research Ethics Committee

Ethics committee address [1]

Office 5E, Perth Children’s Hospital 15 Hospital Avenue, Nedlands WA 6009

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

21/09/2021

Approval date [1]

05/01/2022

Ethics approval number [1]

Summary

Brief summary

BEAT CF is a national, multi-site project which aims to learn and implement , which of the antibiotics commonly used to treat lung infections are best.

There is no single standard of care for managing CF pulmonary exacerbations. Standard care comprises a range of interventions and varies across and within CF treatment centres and may evolve over the course of the PEx Treatment Platform.
At the time of initiation of the PEx Treatment Platform Protocol, management of pulmonary exacerbations generally involves the use of one or more intravenous (IV) antibiotic therapies. 

Most Australian clinicians manage pulmonary exacerbations with an antipseudomonal beta-lactam or carbapenem, combined with a non-beta lactam antibiotic - most typically the aminoglycoside tobramycin given intravenously (IV). Tobramycin can also be given via inhalation. Inhaled tobramycin is widely used for outpatient management, it is rarely used as part of inpatient management of PEx.

This particular domain to the BEAT CF PEx treatment platform aims to find out if there is any gain in providing tobramycin in addition to ‘backbone’ antibiotic therapy.  Also, it will assess there is any difference in giving tobramycin by the IV or inhaled route, and whether no tobramycin is non-inferior to the IV or inhaled tobramycin.

Some clinicians reserve the use of IV aminoglycoside for patients known to be colonised with Pseudomonas aeruginosa. Some, but not all, clinicians use the results of microbiology and in vitro susceptibilities to guide antibiotic selection. Many centres provide additional antibiotic cover targeted to specific pathogens, but only if identified on sputum microbiology, e.g. for Stenotrophomonas maltophilia or Staphylococcus aureus.

The duration of IV antibiotic therapy is typically 14 days, and generally ranges from 10 days to 21 days. A recent RCT found evidence that 10 days was non-inferior to 14 days of IV antibiotics therapy in those with a rapid treatment response, and found no evidence that 21 days was superior to 14 days of IV antibiotics in those without a rapid treatment response.

The primary objectives, outcomes and endpoints for the PEx Cohort were informed by a systematic review of the literature and involvement of key clinical and consumer stakeholders.

Trial website

www.beatcf.org.au

Trial related presentations / publications

Public notes

BEAT CF is a modular and hierarchical project. At the highest level of the hierarchy is the BEAT CF PEx Cohort. This domain specific appendix is one of the lower levels of the hierarchy. Lower levels build upon, and provide detail and specificity to, the higher level. Lower level documents (e.g. Domain specific appendices) must be read in conjunction with the higher level documents (PEx Core Protocol and PEx Treatment Platform).

Contacts

Principal investigator

Name

Prof Thomas Snelling

Address

University of Sydney Faculty of Medicine and Health School of Public Health Edward Ford Building Camperdown Campus NSW 2006

Country

Australia

Phone

+61 2 9563 6886

Fax

tom.snelling@sydney.edu.au

Contact person for public queries

Name

Thomas Snelling

Address

University of Sydney Faculty of Medicine and Health School of Public Health Edward Ford Building Camperdown Campus NSW 2006

Country

Australia

Phone

+61 2 9563 6886

Fax

tom.snelling@sydney.edu.au

Contact person for scientific queries

Name

Thomas Snelling

Address

University of Sydney Faculty of Medicine and Health School of Public Health Edward Ford Building Camperdown Campus NSW 2006

Country

Australia

Phone

+61 2 9563 6886

Fax

tom.snelling@sydney.edu.au

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

No/undecided IPD sharing reason/comment

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically